Mainstream media rarely if ever keep the same energy they have when white women go missing if the people who have disappeared are Black women or girls.
(Source NewsOne):
As outspoken Black people, we’re often asked: Why make everything about race?
It must be an easy question to ask when you’re white and severely limited in the capability of fathoming what marginalization looks and feels like since whiteness is America’s default. So when any given situation arises—whether it be a case of police brutality, a school fight, a crime committed, a lost job, an application rejection or what have you—and Black people wonder out loud how things would be different if the people involved were of a different race, we’re often met with rolled eyes, willful indifference or outright scorn and condemnation for “race-baiting.”
Many of you have probably heard about the story of 22-year-old Gabrielle Petito, the woman who left New York on July 2 for a months-long cross-country trip full of sightseeing and camping with her fiancée, 23-year-old Brian Laundrie. If you’re not familiar with Petito, you can simply Google her name and see her name, face and story pop up on the New York Times, the New York the spread of the Delta variant and the substantial threat it poses to children,” Bourla continued.
“Since July, pediatric cases of COVID-19 have risen by about 240 percent in the U.S. – underscoring the public health need for vaccination. These trial results provide a strong foundation for seeking authorization of our vaccine for children 5 to 11 years old, and we plan to submit them to the FDA and other regulators with urgency.”
The trial included 2,268 participants ages 5 to 11 and used a two-dose regimen of the vaccine administered 21 days apart.
The trial used a 10-microgram dose – smaller than the 30-microgram dose that has been used for those 12 and older.
It was designed to evaluate the safety, tolerability, and immunogenicity of the Pfizer-BioNTech vaccine on a two-dose schedule (approximately 21 days apart) in three age groups: ages 5 to 11 years; ages 2 to 5 years; and ages 6 months to 2 years. Based on the Phase 1 dose-escalation portion of the trial, children ages 5 to 11 years received two-dose schedule of 10 µg each while children under age 5 received a lower 3 µg dose for each injection in the Phase 2/3 study.
The trial enrolled children with or without prior evidence of SARS-CoV-2 infection.
“We are pleased to be able to submit data to regulatory authorities for this group of school-aged children before the start of the winter season,” said Dr. Ugur Sahin, CEO and co-founder of BioNTech.
“The safety profile and immunogenicity data in children aged 5 to 11 years vaccinated at a lower dose are consistent with those we have observed with our vaccine in other older populations at a higher dose.”
